Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner
Li, Chen, Vong, Zhao et al. show that glucagon-like peptide-1 receptor agonist reverses transcriptomic aging signatures in mouse glial and neurovascular cells. This study suggests that glucagon-like peptide-1 receptor agonists may be considered as a therapeutic option for patients at risk of age-rel...
Guardado en:
Autores principales: | Zhongqi Li, Xinyi Chen, Joaquim S. L. Vong, Lei Zhao, Junzhe Huang, Leo Y. C. Yan, Bonaventure Ip, Yun Kwok Wing, Hei-Ming Lai, Vincent C. T. Mok, Ho Ko |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b6e03838a0f54cd39260f2154383d3c8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeting GLP-1 receptor trafficking to improve agonist efficacy
por: Ben Jones, et al.
Publicado: (2018) -
Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chee W Chia, et al.
Publicado: (2009) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Lisa M Neff, et al.
Publicado: (2010) -
Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Mette Simone Aae Madsen, et al.
Publicado: (2019)